BRIEF published on 01/21/2025 at 18:05, 1 year 6 months ago Résultats Positifs pour l'Essai Clinique de MaaT033 Biotechnologie Essai Clinique Sécurité Oncologie MaaT033
BRIEF published on 01/21/2025 at 18:05, 1 year 6 months ago Positive Results for MaaT033 Clinical Trial Biotechnology Security Oncology Clinical Trial MaaT033
PRESS RELEASE published on 01/21/2025 at 18:00, 1 year 6 months ago Informations privilégiées / Autres communiqués MaaT Pharma annonce un résultat positif du 2ème DSMB pour l'essai clinique de Phase 2b de MaaT033 pour patients recevant une allo-GCSH Essai Clinique Sécurité MaaT Pharma Tolérabilité Patients
PRESS RELEASE published on 12/10/2024 at 02:30, 1 year 7 months ago Inside Information / Other news releases
BRIEF published on 10/15/2024 at 07:35, 1 year 9 months ago Conclusion du recrutement pour l'essai clinique de MaaT Pharma Essai Clinique MaaT Pharma MaaT013 Avis DSMB Traitement AGvH
BRIEF published on 10/15/2024 at 07:35, 1 year 9 months ago MaaT Pharma Clinical Trial Recruitment Concluded Clinical Trial MaaT Pharma MaaT013 DSMB Notice AGvH Treatment
PRESS RELEASE published on 10/15/2024 at 07:30, 1 year 9 months ago Informations privilégiées / Autres communiqués MaaT Pharma annonce la fin du recrutement de son essai de Phase 3 ARES pour MaaT013 dans le traitement de la maladie aiguë du greffon contre l'hôte. Premiers résultats attendus en janvier 2025 MaaT Pharma MaaT013 Phase 3 ARES Maladie Aiguë Greffon Contre L'hôte
PRESS RELEASE published on 10/15/2024 at 07:30, 1 year 9 months ago Inside Information / Other news releases MaaT Pharma completes recruitment of its ARES Phase 3 Trial for MaaT013, a treatment for Acute Graft-versus-Host Disease, with topline results expected in January 2025 Clinical Trial MaaT Pharma MaaT013 ARES Phase 3 Trial Acute Graft-versus-Host Disease
PRESS RELEASE published on 09/20/2024 at 09:07, 1 year 10 months ago Rapport Financier Semestriel 2024
BRIEF published on 09/04/2024 at 07:35, 1 year 10 months ago MaaT Pharma annonce sa participation à des conférences investisseurs et médicales en septembre Investisseurs Conférence Médicale Thérapies MET Transplantation Cellulaire Cancers
Published on 07/22/2026 at 15:00, 15 hours 46 minutes ago Karbon-X Secures Technical Advisory Engagement for Nature-Based Carbon Project in Libya
Published on 07/22/2026 at 15:00, 15 hours 46 minutes ago Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)
Published on 07/22/2026 at 14:35, 16 hours 11 minutes ago Wi2Wi Reports Significant Manufacturing Yield Improvement in Q2 2026
Published on 07/22/2026 at 14:30, 16 hours 16 minutes ago As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola
Published on 07/23/2026 at 06:30, 16 minutes ago Cembra reports 6% increase in net income in the first half of 2026 and acquires the substantial part of Santander’s Swiss auto financing business
Published on 07/23/2026 at 06:30, 16 minutes ago Press release: Leonteq returns to profitability in H1 2026
Published on 07/23/2026 at 06:30, 16 minutes ago Bystronic accelerates transformation amid structural market changes
Published on 07/23/2026 at 06:27, 19 minutes ago SFS Delivers Strong Progress in First Half-Year 2026
Published on 07/23/2026 at 02:05, 4 hours 41 minutes ago JINRO Unveils First Global Campaign "My Favorite JINRO" with V of BTS
Published on 07/22/2026 at 18:19, 12 hours 27 minutes ago Covivio place avec succès 500 M€ d’obligations vertes à 7 ans
Published on 07/22/2026 at 18:19, 12 hours 27 minutes ago Covivio successfully places €500 million of 7-year European Green Bonds
Published on 07/22/2026 at 17:45, 13 hours 1 minute ago Groupe CRIT : 2026 first half revenue: €1.67 billion (+2.3% on an organic basis).
Published on 07/22/2026 at 17:45, 13 hours 1 minute ago Groupe CRIT : Chiffre d’affaires du 1er semestre 2026 : 1,67 Md€ (+2,3% en organique).
Published on 07/22/2026 at 17:40, 13 hours 6 minutes ago Report on share repurchases from 15 to 21 July 2026
